ReproCELL Incorporated (4978.T)
JPY 103.0
(0.0%)
JPY 103.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 741.03 Million JPY | -5.07% |
| 2022 | 780.62 Million JPY | -7.57% |
| 2021 | 844.53 Million JPY | 28.65% |
| 2020 | 656.43 Million JPY | 32.64% |
| 2019 | 494.89 Million JPY | 18.16% |
| 2018 | 418.84 Million JPY | 19.88% |
| 2017 | 349.37 Million JPY | -28.05% |
| 2016 | 485.59 Million JPY | -30.67% |
| 2015 | 700.45 Million JPY | 37.6% |
| 2014 | 509.04 Million JPY | 127.84% |
| 2013 | 223.42 Million JPY | 44.74% |
| 2012 | 154.36 Million JPY | 123.06% |
| 2011 | 69.2 Million JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 761 Million JPY | 2.69% |
| 2023 Q3 | 627.42 Million JPY | -5.49% |
| 2023 Q4 | 741.03 Million JPY | 18.11% |
| 2023 Q1 | 709.47 Million JPY | -9.11% |
| 2023 Q2 | 663.87 Million JPY | -6.43% |
| 2023 FY | 741.03 Million JPY | -5.07% |
| 2022 Q3 | 557.45 Million JPY | -42.54% |
| 2022 Q1 | 690.97 Million JPY | -18.18% |
| 2022 FY | 780.62 Million JPY | -7.57% |
| 2022 Q4 | 780.62 Million JPY | 40.03% |
| 2022 Q2 | 970.12 Million JPY | 40.4% |
| 2021 FY | 844.53 Million JPY | 28.65% |
| 2021 Q1 | 492.37 Million JPY | -24.99% |
| 2021 Q2 | 676.36 Million JPY | 37.37% |
| 2021 Q4 | 844.53 Million JPY | 51.2% |
| 2021 Q3 | 558.55 Million JPY | -17.42% |
| 2020 Q3 | 546.9 Million JPY | -8.91% |
| 2020 Q4 | 656.43 Million JPY | 20.03% |
| 2020 FY | 656.43 Million JPY | 32.64% |
| 2020 Q1 | 543.08 Million JPY | 9.74% |
| 2020 Q2 | 600.42 Million JPY | 10.56% |
| 2019 FY | 494.89 Million JPY | 18.16% |
| 2019 Q3 | 433.47 Million JPY | 8.51% |
| 2019 Q4 | 494.89 Million JPY | 14.17% |
| 2019 Q1 | 347.55 Million JPY | -17.02% |
| 2019 Q2 | 399.47 Million JPY | 14.94% |
| 2018 FY | 418.84 Million JPY | 19.88% |
| 2018 Q4 | 418.84 Million JPY | 11.04% |
| 2018 Q3 | 377.2 Million JPY | -5.89% |
| 2018 Q2 | 400.81 Million JPY | 11.78% |
| 2018 Q1 | 358.58 Million JPY | 2.63% |
| 2017 Q3 | 423.45 Million JPY | 3.26% |
| 2017 FY | 349.37 Million JPY | -28.05% |
| 2017 Q1 | 435.3 Million JPY | -10.36% |
| 2017 Q4 | 349.37 Million JPY | -17.49% |
| 2017 Q2 | 410.08 Million JPY | -5.79% |
| 2016 FY | 485.59 Million JPY | -30.67% |
| 2016 Q3 | 484.34 Million JPY | -15.7% |
| 2016 Q4 | 485.59 Million JPY | 0.26% |
| 2016 Q2 | 574.54 Million JPY | -17.24% |
| 2016 Q1 | 694.25 Million JPY | -0.89% |
| 2015 Q2 | 527.22 Million JPY | 11.7% |
| 2015 FY | 700.45 Million JPY | 37.6% |
| 2015 Q1 | 471.99 Million JPY | -7.28% |
| 2015 Q4 | 700.45 Million JPY | -0.8% |
| 2015 Q3 | 706.09 Million JPY | 33.93% |
| 2014 Q3 | 568.24 Million JPY | -16.95% |
| 2014 Q4 | 509.04 Million JPY | -10.42% |
| 2014 Q1 | 207.62 Million JPY | -7.07% |
| 2014 Q2 | 684.23 Million JPY | 229.56% |
| 2014 FY | 509.04 Million JPY | 127.84% |
| 2013 FY | 223.42 Million JPY | 44.74% |
| 2013 Q1 | 198.44 Million JPY | 0.0% |
| 2013 Q2 | 170.35 Million JPY | -14.15% |
| 2013 Q3 | 236.03 Million JPY | 38.55% |
| 2013 Q4 | 223.42 Million JPY | -5.34% |
| 2012 FY | 154.36 Million JPY | 123.06% |
| 2011 FY | 69.2 Million JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 3.24 Billion JPY | 77.177% |
| PRISM BioLab Co.,LTD | 63.41 Million JPY | -1068.617% |
| GNI Group Ltd. | 26.34 Billion JPY | 97.187% |
| Linical Co., Ltd. | 10.3 Billion JPY | 92.809% |
| Trans Genic Inc. | 3.81 Billion JPY | 80.563% |
| MEDINET Co., Ltd. | 590.2 Million JPY | -25.555% |
| Soiken Holdings Inc. | 697.02 Million JPY | -6.314% |
| Cytori Cell Research Institute, Inc. | 3.02 Billion JPY | 75.469% |
| AnGes, Inc. | 2.78 Billion JPY | 73.434% |
| OncoTherapy Science, Inc. | 513.6 Million JPY | -44.28% |
| Nxera Pharma Co., Ltd. | 90.38 Billion JPY | 99.18% |
| Immuno-Biological Laboratories Co., Ltd. | 353.27 Million JPY | -109.763% |
| NanoCarrier Co., Ltd. | 1.64 Billion JPY | 55.086% |
| Carna Biosciences, Inc. | 472.35 Million JPY | -56.88% |
| CanBas Co., Ltd. | 91.98 Million JPY | -705.575% |
| D. Western Therapeutics Institute, Inc. | 1.09 Billion JPY | 32.24% |
| RaQualia Pharma Inc. | 809.83 Million JPY | 8.495% |
| Chiome Bioscience Inc. | 593.73 Million JPY | -24.809% |
| Kidswell Bio Corporation | 4.25 Billion JPY | 82.581% |
| PeptiDream Inc. | 29.11 Billion JPY | 97.455% |
| Oncolys BioPharma Inc. | 566.5 Million JPY | -30.809% |
| Ribomic Inc. | 155.8 Million JPY | -375.603% |
| SanBio Company Limited | 2.25 Billion JPY | 67.137% |
| Healios K.K. | 11.28 Billion JPY | 93.434% |
| BrightPath Biotherapeutics Co., Ltd. | 251.26 Million JPY | -194.916% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 369 Million JPY | -100.822% |
| Delta-Fly Pharma, Inc. | 241.49 Million JPY | -206.849% |
| StemRIM | 187 Million JPY | -296.274% |
| CellSource Co., Ltd. | 677.73 Million JPY | -9.339% |
| FunPep Company Limited | 189.32 Million JPY | -291.409% |
| Kringle Pharma, Inc. | 596.95 Million JPY | -24.135% |
| Stella Pharma Corporation | 1.44 Billion JPY | 48.668% |
| TMS Co., Ltd. | 97.68 Million JPY | -658.562% |
| Noile-Immune Biotech Inc. | 91.49 Million JPY | -709.924% |
| Cuorips Inc. | 200.96 Million JPY | -268.744% |
| K Pharma,Inc. | 209.13 Million JPY | -254.334% |
| Takara Bio Inc. | 11.42 Billion JPY | 93.511% |
| PhoenixBio Co., Ltd. | 917.71 Million JPY | 19.252% |
| StemCell Institute Inc. | 3.85 Billion JPY | 80.755% |
| Japan Tissue Engineering Co., Ltd. | 908.43 Million JPY | 18.427% |
| CellSeed Inc. | 301.04 Million JPY | -146.152% |